ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate UpdateGlobeNewsWire • 03/22/23
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public OfferingGlobeNewsWire • 02/08/23
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public OfferingGlobeNewsWire • 02/06/23
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022GlobeNewsWire • 12/22/22
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/14/22
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate UpdateGlobeNewsWire • 11/07/22
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®GlobeNewsWire • 10/31/22
ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)GlobeNewsWire • 10/20/22
ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ DeviceGlobeNewsWire • 09/22/22
ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial OperationsGlobeNewsWire • 08/23/22
ReShape Lifesciences Inc. (RSLS) CEO Paul Hickey on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/16/22
ReShape Lifesciences™ Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/15/22
ReShape Lifesciences™ to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate UpdateGlobeNewsWire • 08/10/22
ReShape Lifesciences™ Receives FDA 510(k) Clearance for the GIBI HD™ Calibration Tubes for use in Gastric and Bariatric ProceduresGlobeNewsWire • 08/10/22
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive OfficerGlobeNewsWire • 07/27/22
ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross ProceedsGlobeNewsWire • 06/17/22
ReShape Lifesciences and OpenLoop Sign Agreement to Provide Nationwide Virtual Health Services for Weight Loss and Wellness Through reshapecare™GlobeNewsWire • 05/26/22